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Abstract 
Vascular endothelial growth factor (VEGF) is associated with tumour growth and metastasis. Because VEGF is the 
major player in both angiogenesis and vascular permeability and the most explored factor in angio‑inhibitory 
therapies, many expression procedures have been developed to produce functional VEGF165 in convenient yield. In 
this study, recombinant human VEGF165 was cloned and expressed in Escherichia coli (BL21)‑DE3 cells and large scale 
production was performed by fermentation. A high yield of active soluble protein was obtained after protein extrac‑
tion employing both lysozyme and sonication treatment. Inclusion bodies were also isolated from the cell lysate and 
subjected to a simple protocol of solubilisation and refolding. Single‑step purification was performed using nickel 
affinity chromatography and the purified proteins were able to recognize monoclonal Anti‑poly‑His antibody. The 
biological activity of the VEGF165 was successfully tested using the Chicken chorioallantoic membrane assay, wound‑
healing migration and proliferation assay on human umbilical vein endothelial cells (HUVEC).
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Introduction
Angiogenesis is considered as a complex multistep pro-
cess involving the growth of blood vessels from the exist-
ing vasculature (Adair and Montani 2010). Formation 
of new blood vessels can takes place under both normal 
physiological conditions such as embryonic develop-
ment, endometrial and placental proliferation, growth 
and tissue repair, as well as pathological ones, including 
cancer vascularization. The promotion of tumour growth 
is dependent on the expression of growth factors in the 
microenvironment like vascular endothelial growth fac-
tor (VEGF), heparin-binding fibroblast growth factor 
(FGF), and platelet-derived endothelial cell growth fac-
tor (PD-ECGF) (Niu and Chen 2010). VEGF ranks as 
key inducer of angiogenesis and central mediator that 
promotes vascular permeability (Schmitz et  al. 2006). 
Several proteins including VEGF-A to D and placental 
growth factor (PlGF) compose the VEGF family. They do 
not share high homology but they share cysteine “knot 
motif” comprising eight conserved cysteine residues. 
VEGF-A binds to VEGFR-1 and -2, mediating the acti-
vation of all pathways required in angiogenesis. VEGF-A 
which commonly referred to as VEGF, was firstly isolated 
in 1989 from medium conditioned by bovine pituitary 
follicular cells (Ferrara and Henzel 1989) and described 
in highly vascularized tumours where its expression is 
stimulated by hypoxia (Shweiki et  al. 1992). The VEGF 
pre-mRNA is transcribed from a single gene containing 8 
exons, is spliced and expressed as various isoforms owing 
to alternative splicing of exon 6 and 7. These two exons 
determine the VEGF fate, either being associated to cell 
surface or being secreted and associated to the extracel-
lular matrix (Roodink and Leenders 2010). There are at 
least 4 principal variants VEGF121, VEGF165, VEGF189 
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and VEGF206 with the numerals denoting the number of 
amino acids in the mature peptide (Roskoski 2007; Fer-
rara et al. 1992).
VEGF165, the most abundant isoform with VEGF121, 
is secreted and represents the most relevant promoter 
of tumour vascularization as it exerts several effects 
in different pathways required in angiogenesis such as 
endothelial cell migration, proliferation, tube formation 
and survival (Papetti and Herman 2002) and is therefore 
the focus of intense investigation. It has been reported 
that the quantification of the total VEGF mRNA expres-
sion by real-time reverse transcription PCR revealed 
that VEGF121 and VEGF165 mRNA were up-regulated in 
various neoplasm compared to normal tissue (Zygalaki 
et  al. 2007; Hervé et  al. 2008). VEGF121 and VEGF165 
were also found to be the most over-expressed iso-
forms in both colonic and lung carcinoma (Cheung et al. 
1998). VEGF189 and VEGF206 are poorly secreted and 
are essentially cell associated although their peptide sig-
nal sequence is identical to that found in VEGF121 and 
VEGF165 (Houck et al. 1991).
In 1971, Folkman suggested the idea that anti-angio-
genic therapies could be used as a highly promising and 
effective approach in cancer treatment (Folkman 1971). 
VEGF165 showing strong mitogenic potency to vascu-
lar endothelial cells is used to direct therapy in a wide 
range of cancers. On the basis of this pioneering hypoth-
esis, numerous studies were carried out to provide a fast 
and easy way to produce this therapeutic protein. VEGF 
is a highly conserved disulfide-bonded glycoprotein 
with a molecular mass of 43  kDa consisting of an anti-
parallel homodimer structure (Vicari et  al. 2011). The 
VEGF belonging to the PDGF family is characterized by 
the presence of eight conserved cysteine residues impli-
cated in intra- and inter-chain disulfide bonds (Keyt et al. 
1996).
Since the functional potency of VEGF165 is not depend-
ent on the N-linked glycosylation at Asn75 residue, 
eukaryotic expression platform is not required for VEGF 
recombinant protein production (Claffey et  al. 1995). 
Many bacterial expression systems have been developed 
to achieve high yield as well as high quality and func-
tional potency of the VEGF165. It was generally reported 
that expression resulted in most of cases in the formation 
of inclusion bodies which represented the primary source 
of the expressed protein (Gast et  al. 2011). Escherichia 
coli which remains one of the most attractive cell hosts, 
have been widely utilized for production of recombinant 
His-tagged proteins.
In the current study, we report on soluble His-tagged 
VEGF165 protein that was successfully expressed in E. 
coli (BL21)-DE3. Key factors for efficient production 
were assessed and optimization of cell growth conditions 
and media were sought. Several practical methods have 
been implemented to ensure high cell-density cultiva-
tion. Our methods allow us to consistently obtain high 
yield of biological active VEGF165. More importantly, 
different protein extraction procedures with optimized 
conditions were performed to achieve high solubility of 
the expressed protein. An economically and fast protein 
extraction protocol combining sonication and lysozyme 
treatment was used to facilitate soluble VEGF165 extrac-
tion. Moreover, expression of VEGF165 in E. coli (BL21)-
DE3 often results in accumulation of the recombinant 
protein as insoluble aggregates. We describe here an eco-
nomic and efficient process for solubilisation and refold-
ing of the VEGF165 aggregates.
Materials and methods
Strains and culture conditions
pGEMT-easy and pET-21a (+) vectors were used respec-
tively to clone and to express the VEGF splice variants 
proteins. E. coli strains Top10 (F-mcrAΔ(mrr-hsdRMS-
mcrBC) φ80lacZΔM15 ΔlacX74 nupG recA1 araD139 
Δ(ara–leu)7697 galE15 galK16 rpsL(StrR) endA1 λ-) and 
BL21(DE3) (F–ompT gal dcmlonhsdSB(rB-mB-) λ(DE3 
[lacI lacUV5-T7 gene 1 ind1 sam7 nin5]) were used as 
recipient for cloning and expression vectors respectively.
Culture media were LB (Luria-Bertani):10  g/l bacto-
tryptone, 5  g/l yeast extract, 5  g/l NaCl; 2YT: 17  g/l 
bacto-tryptone, 10 g/l yeast extract, 5 g/l NaCl. LBA and 
2YTA: LB and 2YT containing 100 µg/ml ampicillin.
The VEGF165 coding sequence, isolated from MCF7 cell 
lines, was 100% identical to the human VEGF165, already 
published (Piotrowski et  al. 2015) under the accession 
number NM_001287044.1, was cloned downstream of 
the T7lac promoter and transformed into E. coli BL21-
(DE3). Recombinant strains were cultivated on 2YTA 
medium and induced by the addition of 1 mM of IPTG at 
37 °C for 20 h.
Amplification of VEGF splices variants
Polymerase chain reaction (PCR) was performed with a 
common forward primer F1 located in exon 2 and a com-
mon reverse primer R1 located in exon 8; both exon 2 
and exon 8 are parts of the conserved region of all VEGF 
splice variants (Table  1). R1 primer contains at its end 
six His residues followed by a stop codon. These primers 
were designed to amplify the coding region of all VEGF 
isoforms and to contain restriction endonuclease sites 
(BamHI and XhoI) for sub-cloning into pET21a vectors. 
The target sequences (see “Results” section) were ampli-
fied in a 25 µl reaction volume containing either 1 µl of 
each cDNA (already available in our laboratory) or 1  µl 
of diluted Plasmid DNA (after cloning into pGEMT-
easy vector), 0.2  µM of each primer, 200  µM dNTP, 1X 
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Dream Taq PCR Buffer and 1 unit of Dream Taq Poly-
merase. Amplification was carried out in a DNA thermo-
cycler (Biometra) with initial denaturation at 94  °C for 
5 min, followed by 37 cycles of 30 s denaturation at 94 °C, 
annealing for 30 s at 60 °C, extending for 40 s at 72 °C and 
a final cycle of 7 min extension at 72 °C. The PCR prod-
ucts were analysed by electrophoresis on a 2% agarose gel 
that was subsequently visualized under UV illumination 
after ethidium bromide staining.
Cloning and DNA sequencing of RT‑PCR products
The PCR fragment, amplified on cDNA from MCF7 
cell line, was firstly cloned into the pGEMT-easy vector 
(Promega). Ligation product was transformed into com-
petent E. coli Top10 cells and plated on LBA. A fraction 
(1/20) of each colony-plasmid was amplified with Dream 
Taq DNA polymerase using F1 and R1 primers. As these 
primers can detect all VEGF splice variants, each vari-
ant was identified by PCR screening and was verified by 
DNA sequencing using universal and reverse primers 
(Table 1). Thereafter, the VEGF165 variant was sub-cloned 
in pET-21a using the BamHI and XhoI restriction sites.
Fermentation of the recombinant strain expressing the 
VEGF165
A 7 l stirred tank bioreactor (Infos, AG GH-4103 Bott-
mingen, Switzerland) equipped with air flow, tem-
perature, dissolved oxygen concentration, pH and 
agitation control was utilized to produce elevated lev-
els of VEGF165. The fermentation was carried out with 
a working volume of 4 l. In the batch cultivation, the 
temperature was maintained at 37  °C and dissolved 
oxygen was kept above 20% of medium saturation by 
air supply and agitation rate variation (400–600  rpm). 
To decrease foam production Silicone 426 R antifoam 
(Prolabo, Paris, France) was added. The initiated pH 
of the medium was 7 and the pO2 was 98%. After 7  h, 
pO2 decreased to 43%. When the OD600nm of the culture 
reached 0.7, IPTG was added at a final concentration of 
1  mM. The induction phase was maintained for more 
than 16 h. After 16 h, pO2 continue to decrease to 1%. 
When pO2 increased to 9% (18  h of induction phase) 
the growth rate was found to slow down. At this pO2, 
the growth of E. coli cells was stopped and the cell pellet 
was collected by centrifugation at 6000 rpm for 20 min 
and stored at −20 °C.
Cell disruption
In order to optimize the protocol of extraction of the 
recombinant VEGF165 from the cell pellet, five methods 
were adopted: M1: Alumina treatment; M2: lysozyme 
treatment; M3: sonication in PBS; M4: sonication in Lysis 
Buffer; M5: lysozyme treatment followed by sonication in 
lysis Buffer treatment. Induced cultures were centrifuged 
at 6000 rpm for 20 min for each of these methods.
A mechanical cell shearing performed by the abrasive 
effect of the alumina powder was adopted in M1. In that 
case, after pelleting, cells frozen at −20  °C (1.5  g) and 
subsequently thawed in a chilled mortar were grinded 
energetically for 15  min with Alumina powder w/w 
(Sigma-Aldrich, Munich, Germany) using a pestle until 
the mixture formed a fairly stiff paste (Hughes 1950). 
The cell paste was re-suspended in 2 ml of PBS 1X buffer 
containing 2 mM PMSF. Alumina, unbroken cells as well 
as cell debris were decanted after a low speed centrifuga-
tion at 3000 rpm for 10 min and the supernatant (crude 
lysate) was saved.
Osmotic lysis of bacterial cells was adopted in M2. 
After washing with buffer A, containing 500 mM sucrose, 
25  mM Tris–HCl pH 8, 10  mM EDTA, the cell pellet 
was re-suspended in this hypertonic solution and then 
treated with lysozyme (5  mg/ml). Protoplasts were har-
vested by centrifugation at 4000  rpm for 10  min and 
burst with an osmotic imbalance created by an hypotonic 
solution (buffer B) composed of 25 mM Tris–HCl pH 8, 
then phenyl methyl-sulfonyl fluoride (PMSF) was added. 
The remaining non-burst cells and cells debris were cen-
trifuged at 3000 rpm for 10 min.
Additionally, a high operating pressure using a “Vibra 
cell VCX 750 sonicator was performed for 30 min at 60% 
amplitude with PBS in M3 and with lysis buffer com-
posed of 50 mM Tris–HCl pH 8, 150 mM NaCl, 2 mM 
EDTA, 1% Triton, 1% PMSF in M4.
Alternatively, combining sonication and lysozyme 
treatment was carried out in M5 by first treating the pel-
leted protoplasts with lysis buffer (50 mM Tris–HCl pH 
8,  150  mM NaCl, 2  mM EDTA, 1% Triton, 1% PMSF) 
and then sonication for 30  min at 60% amplitude. The 
resulting protein extract was centrifuged at 3000 rpm for 
10 min to remove unbroken cells and cell debris.
For all extraction protocols, after the mild centrifuga-
tion (3000 rpm for 10 min) the supernatant, called crude 
lysate, is clarified by centrifugation at 13,000  rpm for 
10  min. The supernatant represented the total soluble 
protein extract while the pellet represented the IB (inclu-
sion bodies).
Table 1 Primers used in this work
DNA used Primers
pGEMT easy vector Universal 5′GTTTTCCCAGTCACGACGTTGTA3′
Reverse 5′AGCGGATAACAATTTC3′
cDNA F (ex2) 5′GGATCCGCACCCATGGCAGAAGGAGGA
R (ex8) 5′CTCGAGTCAGTGGTGGTGGTGGTGGTGCCG 
CCTCGGCTTGTCACATCT
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Inclusion bodies isolation
The IB pellet material collected from the large scale pro-
duction (700 ml of culture) was predominantly used for 
VEGF165 solubilisation and refolding experiments. It 
was re-suspended in 50  ml of buffer containing 50  mM 
Tris-HCl pH 8, 50  mM NaCl, 1  mM EDTA, 1% Triton 
X-100. After washing with the same buffer but without 
Triton X-100, the inclusion bodies were collected by 
centrifugation at 8000 rpm for 10 min and subsequently 
subjected to the solubilisation step by adding of 25 ml of 
8M urea and 5% β-mercaptoethanol (βME). The suspen-
sion was stirred overnight at 4  °C and then centrifuged 
at 8000 rpm at 4 °C for 10 min. The solubilized proteins 
were then dialyzed at 4 °C against 2 l of buffer containing 
25  mM Tris pH8, 50  mM NaCl. The dialysis buffer was 
changed four times to sufficiently allow VEGF165 refold-
ing. The remaining insoluble material was eliminated by 
centrifugation at 8000 rpm for 10 min.
VEGF165 purification
A nickel affinity chromatography was used to purify the 
VEGF proteins. The total protein extract (either from 
total soluble proteins or from solubilised IB) was loaded 
on His Trap™chelating HP 1 ml column (GE healthcare 
life sciences) with a flow rate of 1 ml/min. The resin was 
washed with 30  ml binding buffer (20  mM NaH2PO4 
Na2HPO4, 500 mM NaCl, 10 mM Imidazole, pH 7.4) to 
enable elution of non-specifically-bound proteins. Finally, 
the His-tagged proteins were eluted from the resin with 
Imidazole linear gradient from 10 to 500  mM in Elu-
tion Buffer (20 mM NaH2PO4 Na2HPO4, 500 mM NaCl, 
pH  7.4). The purity of collected fractions was assessed 
by SDS-PAGE, and protein concentration was checked 
using Bradford’s method.
SDS‑PAGE and western blot analysis
The expression of the recombinant VEGF165 protein in E. 
coli BL21 cells was evaluated by SDS-PAGE and Western 
Blot. The total protein extract (30  µg) and the purified 
protein were mixed to loading buffer, heated for 5  min 
and applied on the gel. 15% SDS-PAGE electrophore-
sis was conducted in buffer (25 mM Tris; 250 mM Gly-
cine; 1‰ SDS) for 2 h. Separated proteins were directly 
electro-blotted onto a nitrocellulose membrane in buffer 
(39  mM Glycine; 48  mM Tris; 0.037% SDS; Metha-
nol 20%) for 1  h at constant voltage (15  V). The mem-
brane was stained with Ponceau S then distained using 
bi-distilled water, to verify protein-transfer efficiency. 
The membrane was blocked for 1  h at room tempera-
ture with 5% skim milk in phosphate-buffered saline 
(0.9% NaCl in 10  mM phosphate buffer, pH 7.4) with 
Tween-20. Immuno-blotting was carried out by incu-
bating the membrane with primary antibody Anti-His 
Sigma-Aldrich diluted to 1:5000; then with the appropri-
ate Horseradish Peroxidase conjugated secondary anti-
body diluted to 1:5000. Peroxidase activity was detected 
using the Amersham enhanced chemo-luminescence 
system and autoradiography or densitometric analy-
sis performed by the Versadoc MP4000 imaging system 
(Bio-Rad).
In vitro endothelial cell proliferation assay
Human umbilical vein endothelial cells (HUVEC) were 
maintained in RPMI 1640 medium supplemented with 
10% fetal calf serum (FCS) in a humidified incubator with 
5% CO2. Cells were seeded at a density of 5000 cells per 
well and allowed to grown over-night at 37 °C in a 96-well 
tissue culture plates until reaching a pre-established 
confluence.
Various concentrations of recombinant human 
VEGF165 (200 and 500  ng) were added and incubated 
with HUVEC cells for 72  h. Four duplicate wells were 
set up for each condition and three independent assays 
were performed. The proliferation of endothelial cells 
was evaluated with the MTT test; the treated cells were 
incubated with 0.5 mg/ml MTT for 2 h at 37 °C. Culture 
medium was removed carefully from each well and 100 µl 
of DMSO was added. The plate was then gently agitated 
until the color reaction was uniform and OD560nm was 
measured using a microplate reader.
Chicken chorioallantoic membrane assay
Chick embryos from 3-day-old eggs were opened and 
placed in double Petri dishes with added water to main-
tain eggs humidified. After 5  days at 37  °C, filter paper 
disks (diameter 6  mm) soaked in buffer (0.9% NaCl), 
200  ng and 500  ng of recombinant human VEGF165 
were applied on the chicken chorioallantoic membrane 
(CAM). After 48 h, spontaneous and induced angiogen-
esis were observed and photographed with a digital cam-
era at 10× magnification. The response was quantified by 
scoring the extent of vascularization using the software 
program ImageJ.
Wound‑healing migration assay
Human umbilical vein endothelial cells were cultivated 
at 37 °C in 48-well plates in RPMI 1640 medium supple-
mented with 10% fetal calf serum (FCS) and maintained 
overnight in a humidified incubator (5% CO2). Cells 
were seeded at a density of 5000 cells per well. The next 
day, monolayers created were carefully scratched using 
a 20-μl microtip. The cellular debris was subsequently 
removed by washing with PBS. The cells were thereafter 
treated with or without recombinant VEGF165 (200  ng) 
in serum free RPMI medium for an additional 12  h. 
Cell images for each condition were taken with a digital 
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camera connected to an inverted microscope LEICA 
(×10 objective). The software program ImageJ was used 
to determine the percentage of wound healing for each 
condition.
Statistical analysis
Data is presented as the mean ± SEM of five independent 
experiments. Statistical significance was analyzed using 
unpaired Student’s t test using STATISTICA 6. p < 0.05 
was considered statistically significant and is indicated 
with asterisks over the value (**p < 0.05 and ***p < 0.001).
Results
Amplification of the VEGF splices variants
Total RNA was extracted from four cell types: the 
MCF7 cell line, two tumoral biopsies (breast and colo-
rectal cancer) and one adjacent normal tissue from a 
colorectal cancer patient. The relative abundance of the 
various VEGF splice variants was determined by RT-
PCR using cDNA available in our laboratory. VEGF165 
and VEGF121 were the major variants expressed fol-
lowed by VEGF189 (Fig.  1a). The obtained result is in 
keeping with findings of various studies which showed 
that VEGF165 VEGF121 and VEGF189 were routinely the 
most expressed. Our results showed that only VEGF121 
was weakly expressed in distant normal tissue whereas 
a high level expression of VEGF121 and VEGF165 in 
tumour tissues was observed (Fig. 1a). In this context, 
it was reported that VEGF121 appeared to be mostly 
expressed in normal tissue. It was also found that in 
colorectal tumours, VEGF121 expression was similar in 
both normal and tumour tissue, whereas VEGF165 was 
detected at higher level in tumour tissue (Cressey et al. 
2005).
The PCR product mixture obtained after amplifica-
tion of the MCF7 cDNA was ligated into pGEMT easy 
vector and cloned in E. coli Top10. Several clones were 
analysed by PCR using the same primers (Fig.  1b) and 
subsequently sequenced. As expected, the three types 
of VEGF are represented in the different clones and 
their sequences were completely identical to the pub-
lished ones, i.e. the VEGF165 with accession number 
NM_001287044.1 (Piotrowski et al. 2015).
Heterologous expression VEGF165using the pET‑21a(+) 
vector
It should be recalled that the recombinant VEGF165 is 
produced here as a His-Tagged fusion protein. The condi-
tions of culture and induction were optimized at differ-
ent levels: the culture medium (LB or 2YT), the inducer 
concentration (0.4 and 1 mM IPTG), the post-induction 
temperature (25, 30 or 37 °C) and the duration of the cul-
ture post-induction.
The optimal culture conditions during the induction 
phase of the recombinant VEGF165 were the following: 
1 mM of IPTG as inducer in 2YT medium, at 37  °C for 
20 h induction time (Fig. 2a). Expression was verified by 
SDS-PAGE and western blot (Fig. 2b), showing that after 
IPTG induction for 20 h and only in the 2YT medium, a 
protein was over-expressed. It migrated, under reducing 
condition, with an apparent molecular weight of 23 kDa. 
This band was immuno-recognized by the anti-His-
tag antibody. This antibody was also able to detect the 
homodimeric form of the VEGF165.
Optimization of the VEGF165 protein extraction
We aimed to compare different extraction protocols 
of recombinant VEGF. Figure  3a shows that when only 
Fig. 1 Analysis of electrophoretic profiles. a Agarose gel profile of products resulting from PCR amplification of the VEGF transcripts present in 
tumor tissue: human breast cancer cell line MCF7 (lane 2), human colorectal cancer cells (lane 4) and human breast cancer cells (lane 5) and in 
distant‑tumor tissue (lane 3) M molecular‑mass marker (100 pb DNA ladder; Fermentas); lane 1 PCR negative control (sample without DNA). b 
Agarose gel showing PCR products from amplification of the positive clones obtained after ligation to pGEMT easy vector. Lane 1 VEGF121, lane 2/3 
VEGF165, lane 4/5 VEGF189, T‑: PCR negative control (sample without DNA)
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sonication was applied, the recombinant protein is faintly 
seen while it was almost absent in M1 and M2 (using 
only alumina or lysozyme). The yield of the recombinant 
VEGF165 protein, estimated by SDS-PAGE and Western 
Blot, was higher when using subsequently lysozyme and 
sonication treatments, compared to all other methods. The 
most interesting result in this condition concerned the “clar-
ification” of the majority of the bacterial background, leav-
ing almost only the lysozyme and the recombinant VEGF165 
and other faint contaminant proteins (Fig. 3a, lane 5).
VEGF165 purification using Nickel‑affinity chromatography
Being His-Tagged, the VEGF165 was purified on a His 
Trap column. The total protein extract, from the best 
method M5, was applied to the column and the fractions 
were eluted using Imidazole gradient (10–500 mM) and 
analyzed on 15% SDS-PAGE (Fig. 3b). The VEGF165 pro-
tein was eluted at 250 mM Imidazole. Western Blot anal-
ysis confirmed that this purified protein corresponded to 
VEGF165 (Fig. 3d, lane 2).
VEGF165 recovery from inclusion bodies
Solubilisation and refolding operations are the most 
important steps that could efficiently convert aggregated 
protein to bioactive form. In our study, a simple solubili-
sation method was performed using a high concentration 
of urea (8  M) and 1% of Triton X-100 to solubilize the 
pellet. To obtain reduced state of the cysteine residues, 
β-mercaptoethanol was used as reducing agent. 1  mM 
EDTA was also added to the solubilisation buffer to pre-
vent metal-catalysed air oxidation of cysteine residues. 
Thereafter, an elaborate method of proteins aggregate 
refolding is needed to ensure a good amount of the bio-
active VEGF165. Therefore, step-wise dialysis was used for 
the renaturation of the recombinant protein. The gradual 
removal of the denatured reagent is the most important 
step as to increase the refolding efficiency of the dena-
tured VEGF165. Figure  3c shows that after renaturation, 
VEGF165 was successfully refolded, facilitating thereby its 
purification. Under reducing conditions, the molecular 
weight of the refolded VEGF165 was 23 kDa. Similarly to 
the soluble VEGF165, we found that elution with 250 mM 
Imidazole resulted in an increased quantity and purity 
of the recombinant protein. Both the monomer and the 
dimer were efficiently eluted.
Finally, we compared the eluted fraction at 250  mM 
Imidazole from the soluble VEGF165 to the refolded 
VEGF165; Fig. 3d shows that they behave similarly by the 
western blot analysis. The batch fermentation process 
yields approximately 1.5  mg/l of purified VEGF165 from 
both supernatant and inclusion bodies.
In vitro HUVEC cells proliferation assay
To examine whether the recombinant human VEGF165 
was able to induce proliferation of HUVEC cells, we 
performed MTT experiment with 200 ng and 500 ng of 
VEGF165. Figure  4 showed that pretreated cells resulted 
in a dose dependent activation of HUVEC cells prolif-
eration. As expected, treatment with 500 ng of VEGF165 
showed significant cell growth activation when compared 
to the untreated cells. VEGF stimulation enhanced signif-
icantly (p ˂ 0.05) HUVEC cells proliferation.
Fig. 2 Effect of culture conditions on the expression of VEGF165 in the pellet (insoluble) and the supernatant (soluble) of centrifuged crude lysates. 
a Insoluble VEGF165 expression at different induction temperature, different IPTG concentration and different medium. Lanes 1–3: insoluble VEGF165 
expression induced with 0.4 mM IPTG in 2YTA medium at the temperature 25, 30 and 37 °C respectively. Lane 4 insoluble VEGF165 expression 
induced with 1 mM IPTG at 37 °C in 2YTA medium. Lanes 5–7 insoluble VEGF165 expressed in LBA medium and induced with 0.4 mM IPTG at 25, 
30 and 37 °C respectively. Lane M protein marker (GE Healthcare UK limited). Lane 8 empty pET 21a vector lysate (control). b SDS‑PAGE (top) and 
Western blot (bottom) analysis of the soluble VEGF165 expression at different induction temperature, different IPTG concentration and different 
medium. Lane 1–3 soluble VEGF165 expression induced with 0.4 mM IPTG in 2YTA medium at the temperature 25, 30 and 37 °C respectively. Lane 
4 soluble VEGF165 expression induced with 1 mM IPTG at 37 °C in 2YTA medium. Lanes 5–6 soluble VEGF165 expressed in LBA medium and induced 
with 0.4 mM IPTG at 25 and 37 °C respectively
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Chicken chorioallantoic membrane assay
To further characterize the pro-angiogenic properties of 
recombinant VEGF165, we performed ex vivo angiogene-
sis using chick chorioallantoic membrane (CAM) assays. 
Upon dissection of the CAM of 8-day-old chick embryos, 
filter paper disks soaked in buffer (0.9% NaCl) used as 
control, 200 and 500  ng of recombinant VEGF were 
applied on the CAM. The spontaneous angiogenesis in 
CAM was observed after 48 h. As illustrated in Fig. 5A, 
recombinant VEGF induced remarkably the number 
of new capillaries and branching vessels in the CAM. 
Furthermore, an increase in the vascular density could 
be observed. Quantification shows that the total vessel 
length was induced by 50 and 100% by 200 and 500  ng 
doses, respectively (Fig. 5A, b and c), compared with the 
untreated conditions (Fig. 5A, a).
In vitro scratch wound assay
Because endothelial cell migration is very important in 
VEGF-associated wound healing, we performed in vitro 
scratch assay employing HUVEC cells. In order to evalu-
ate the functionality of the recombinant VEGF165, cells 
were cultured for 12  h in serum free RPMI medium 
containing or not 200  ng of VEGF165. Compared with 
T12h treated cells with 200  ng VEGF165, the non-
treated HUVEC cells did not significantly migrate into 
the scratched site under any growth factor stimulation. 
Images were analysed for the gap area over time (T0  h: 
Fig. 6Aa, Ab and T12h: Fig. 6Ac, Ad). We showed a high 
statistically significant difference between untreated 
HUVEC cells and those treated with 200  ng VEGF165. 
Our finding shows that HUVEC cells migrate into the 
Fig. 3 VEGF165 expression and purification by SDS‑PAGE analysis under optimal condition. a VEGF165 protein extraction. Lane 1–5 corresponds 
respectively to total protein extracted from conditions M1 Alumina treatment, M2 lysozyme treatment, M3 sonication in PBS, M4 sonication in lysis 
buffer, M5 lysozyme treatment followed by sonication in lysis Buffer treatment. Lysozyme and VEGF165 are indicated. b Soluble VEGF165 Purification. 
Lane 1 soluble cell lysate before purification; lane 2 flow‑through; lanes 3–12: eluted fractions from His‑trap column under reducing conditions. c 
SDS‑PAGE analysis of the eluate from the refolded IB. Lane 1 refolded VEGF165 before purification; lane 2–6 eluted fractions with 250 mM Imidazole. d 
Western blot analysis of the VEGF165 purification. Lane 1 eluate from the refolded VEGF165; lane 2 eluate from the soluble VEGF165 at 250 mM Imida‑
zole; lane 3 eluate from the soluble VEGF165 at 350 mM; lane 4 empty pET21a vector lysate
Fig. 4 Effect of VEGF165 on HUVEC cells proliferation. HUVEC cells 
were grown to confluence and then incubated with serum free RPMI 
medium (used as control), 200 and 500 ng of recombinant VEGF165. 
Significant differences: ** means p < 0.05
Page 8 of 11Taktak‑BenAmar et al. AMB Expr  (2017) 7:33 
scratched site under any growth factor stimulation and 
the wound closure extent to 65% (Fig.  6Ac), while cell 
migration into the free area induced by 200 ng VEGF165 
was significantly increased by 15% and the wound closure 
extent to 80% (Fig. 6Ad, Fig. 6B). The obtained result is 
in keeping with findings of various studies which showed 
that VEGF165 stimulates endothelial cell migration (Pan 
et al. 2014; Van der Meer et al. 2010). This confirms that 
the VEGF produced here is biological active.
Discussion
The production of VEGF165 in significant amounts is 
an important prerequisite for the search, expansion of 
promising and effective anti-angiogenic drugs. Many 
attempts for producing VEGF165 in bacterial system have 
been made. They have mainly focused on the optimiza-
tion of production conditions such as induction tem-
perature, IPTG concentration and time incubation after 
induction (Kang et al. 2013). Generally, low temperature 
ensured the expression of less inclusion bodies and more 
soluble form of recombinant protein but some reports 
found that the soluble recombinant VEGF165 expres-
sion was increased when the cells were incubated at 
37 °C (Lee et al. 2011). Interestingly, we showed that the 
expression of the VEGF165 induced with 1 mM IPTG in 
2YT medium at 37 °C for 20 h increased the percentage 
of the soluble protein. In this expression assay, inclusion 
bodies occurred heavily when the inducing temperature 
was set at 37 °C. We also showed that VEGF protein was 
much more expressed in 2YTA than in LBA medium, 
probably because it was exclusively produced as inclusion 
bodies in LBA condition.
The common objective of a successful heterologous 
expression is generally to balance success rates with 
speed, ease, cost and breadth of use. For this reason, dif-
ferent parameters for VEGF165 expression are needed to 
ensure a high level and a good yield of the recombinant 
protein. The central interest of many works is to optimize 
production conditions such as shaking speed, medium, 
induction temperature, IPTG concentration, but the 
optimization of the protein extraction method remains 
a major challenge for a high percentage of the produced 
Fig. 5 Recombinant VEGF165 induces ex vivo angiogenesis. A The CAM models were prepared using 8‑day‑old chick embryos treated as described 
in method section. Dark circles represent location of applied disks. Filter disks were soaked in (a) 0.9% NaCl; (b) 200 ng of recombinant VEGF; (c) 
500 ng of recombinant VEGF; after incubation for 48 h, CAMs were photographed with a digital camera. Each group contained four CAMs and the 
experiment was repeated three times. B The quantitative measurement of total vessel length was performed on 50% of the total CAM surface 
treated in the absence or in the presence of recombinant VEGF. Significant differences: ** means p < 0.05
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protein. It is apparent that the methods described here 
have, in many instances, to be quite similar especially 
with use of sonication in lysis buffer to extract target pro-
teins. But combining different protein extraction method 
is not frequently used. In this study, we found that com-
bining lysozyme treatment and sonication in lysis buffer 
(M5) could increase the level of the soluble VEGF165. 
More interestingly, the consequence of this method is the 
important clarification of the protein lysate, thereby facil-
itating the purification of the VEGF165. A single step of 
purification using affinity chromatography that does not 
need any organic solvent like acetonitrile was carried out.
Many procedures for producing recombinant human 
VEGF165 in bacterial system were described but resulted 
in most of cases in the production of insoluble inclusion 
bodies which represented the primary source of the tar-
get protein (Gast et al. 2011). With the fact that 30% of 
proteins from E. coli itself cannot be expressed in soluble 
form (Gräslund et al. 2008), it is meant that the main lim-
itations of the recombinant protein expression from bac-
terial cells are the low production levels and low refolding 
yield of the inclusion bodies, leading to biologically inac-
tive recombinant proteins (Bang et al. 2013).
It was reported that aggregation reactions of different 
proteins displayed certain common properties. A strong 
temperature dependence of unfolding enthalpy which 
increases rapidly with temperature was shown. The use of 
low temperature during induction phase could increase 
peptide stability and reduce inclusion bodies formation. 
In contrast to previous studies (Kim et  al. 2007; Zhang 
et  al. 2014) we found that maintaining induction tem-
perature at 37  °C for 20 h led to a low aggregation level 
of the VEGF165 improving its solubility. Nevertheless, 
our protein was expressed largely in the form of inclu-
sion bodies. The protein aggregates was solubilized using 
high concentration of Urea while β-Mercaptoethanol was 
added to split the disulfide bond (that are responsible of 
the inter-subunit aggregation) and to maintain cysteine 
residues in a reduced state. The step-wise dialyses used 
allow protein folding into their native form and decrease 
sufficiently the denaturant concentration.
This insoluble fraction was therefore subjected to a 
simple procedure that overcomes the need of multi-days 
refolding experiments (Lee et  al. 2011). Indeed, these 
authors spent about 7  days of serial dialysis in order to 
recover a refolded protein while our procedure takes only 
48 h.
A single step purification of the refolded VEGF165 was 
thereafter carried out using a Nickel affinity column. 
Similarly to the soluble VEGF165, the refolded protein was 
eluted at 250 mM Imidazole and detected by anti His-tag 
antibodies. On the other hand, the function of VEGF 
in wound repair has been extensively studied. Thereby, 
VEGF stimulates angiogenesis and also influences wound 
closure and epidermal repair. Here, the biological activity 
of the recombinant VEGF165 was verified by chicken chri-
oallantoic membrane assay, scratch wound healing and 
proliferation assay using HUVEC cells. Thus, VEGF165 
Fig. 6 Cell migration in response to VEGF165. A a The free untreated cell area at T0 h. b The gap area of induced cells at T0 h. c untreated cells at 
T12 h. d The cell migration in response to treatment with 200 ng VEGF165 at T12 h. B Histogram showing the percentage of wound healing for each 
condition. Significant differences: *** means p < 0.001
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potency and bioactivity were confirmed by its ability to 
promote endothelial cell migration and proliferation and 
to induce new capillaries and branching vessels in the 
CAM model.
In summary, this study described a simple approach 
for producing recombinant VEGF165 for therapeu-
tic applications. The overall probability of expressing 
human VEGF successfully depends on the variation 
of the large-scale production parameters and also pro-
tein extraction methods that could increase the yield 
and the purity of the soluble protein. Protein extraction 
was a major challenge that could assess the purity of the 
VEGF165 and lead to a simplified purification procedure. 
Overall, a successfully VEGF165 expression in bacte-
rial system within soluble and insoluble fraction with 
fast and low cost procedure was presented to produce 
efficiently a functional VEGF protein for therapeutic 
applications.
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